Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06161610 | Recurrent High Grade Glioma Treated by LITT(REGALITT) | recruiting | N/A | 135 | Beijing Tiantan HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04648462 | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | recruiting | — | 1,500 | Maastricht Radiation OncologyOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04233788 | Metabolic Characterization of Space Occupying Lesions of the Brain(FASTMRSI) | recruiting | — | 55 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04868396 | Patient-derived Glioma Stem Cell Organoids | active not recruiting | — | 60 | Maastricht Radiation OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 134 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06043765 | Reducing Cognitive Impairment in Glioma with Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training(TRUE-GRIT) | recruiting | N/A | 16 | Linda DouwOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06684899 | Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients(KillGlio) | not yet recruiting | — | 40 | IRCCS San RaffaeleOTHER | 0 | Nov 14, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06657027 | Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma(ARTPLAN-GLIO) | not yet recruiting | — | 40 | Hospital del Rio HortegaOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04461938 | Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)(ERGO3) | active not recruiting | N/A | 30 | Goethe UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646211 | High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04070040 | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | recruiting | Phase 2 | 21 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04267978 | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas | recruiting | Phase 2 | 109 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04501705 | Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults | recruiting | N/A | 29 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | recruiting | Phase 2 | 44 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05278715 | Modified CV Regimen in Optic Pathway Glioma | recruiting | Phase 2 | 75 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05836701 | Retrospective Study of Germ Cell Tumors of the Central Nervous System | active not recruiting | — | 500 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06180434 | Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas(SOPRANO) | recruiting | — | 320 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06623565 | Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques(NEXTFRONTIER) | recruiting | N/A | 30 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06620055 | Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas(GLIO-AI) | recruiting | — | 164 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06616727 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM | enrolling by invitation | Phase 1 | 50 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616909 | Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences | active not recruiting | N/A | 120 | National Taiwan University HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06610851 | Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA(GLIBAMIR) | recruiting | — | 20 | University Hospital, CaenOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05512403 | Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics(KING) | recruiting | Phase 3 | 88 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06595186 | JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06595667 | Fluid Responsiveness in Posterior Fossa Tumor Resection: PPV and CVP Guidance | active not recruiting | N/A | 50 | Chiang Mai UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma(ONC-2022-001) | not yet recruiting | Phase 1 / Phase 2 | 86 | Armando Santoro, MDOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06572475 | USPIO Enhanced MR Imaging in CNS Tumours (UMIC)(UMIC) | recruiting | N/A | 17 | Northern Care Alliance NHS Foundation TrustOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06572592 | The Predictive Value of MRI for Adult-type Diffuse Gliomas(MRI; glioma;) | not yet recruiting | — | 200 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT04933422 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | not yet recruiting | Phase 1 | 72 | Crimson Biopharm Inc.INDUSTRY | 0 | Aug 21, 2024 | clinicaltrials |
| NCT01106794 | Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | recruiting | — | 100 | Children's National Research InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06524063 | Targeted Survivin DC Cell Injection for the Treatment of GBM | not yet recruiting | Phase 1 | 9 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 29, 2024 | clinicaltrials |
| NCT05990556 | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients | recruiting | N/A | 20 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06512298 | Plasticizer Exposure and Its Consequences on Health(PEACH) | not yet recruiting | — | 120 | Medical University of ViennaOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06499636 | In Vitro Models From Pediatric Brain Tumors(PBTS23) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06480721 | FET-PET-Guided Management of Pseudoprogression in Glioblastoma(FET-POPPING) | not yet recruiting | N/A | 144 | Veerle RuijtersOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT02619890 | Brain Glioma Registry Combining Clinical and Imaging Information | recruiting | — | 9,000 | Asan Medical CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05768087 | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients | recruiting | N/A | 36 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03899857 | Pembrolizumab for Newly Diagnosed Glioblastoma(PERGOLA) | active not recruiting | Phase 2 | 56 | University of ZurichOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05727605 | Neurocognition After Radiotherapy in CNS- and Skull-base Tumors(NARCiS) | recruiting | N/A | 120 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2024source: clinicaltrials